Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869 · clinicaltrials.gov ↗

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Alectinib

Sponsor

Hoffmann-La Roche